Dyslipidemia

November 18th 2024

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.

November 7th 2024

A 6-year longitudinal study, involving more than 200,000 adults, reported a notable rise in dyslipidemia incidence during the COVID-19 pandemic.

October 21st 2024

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

October 19th 2024

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.